Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Standard BioTools (NASDAQ: LAB) announced that its President and CEO, Michael Egholm, PhD, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The event will be held from January 13th to 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s presentation is scheduled for January 16th, 2024, at 9:45 a.m. PT. A live audio webcast of the presentation will be accessible via the Investor Relations page on the company’s website. An archived recording will also be available for later access on the same page.
Standard BioTools (NASDAQ: LAB) ha annunciato che il suo Presidente e CEO, Michael Egholm, PhD, parteciperà alla 43ª Conferenza Annuale J.P. Morgan Healthcare. L'evento si terrà dal 13 al 16 gennaio presso il Westin St. Francis Hotel di San Francisco, CA. La presentazione del Dr. Egholm è programmata per 16 gennaio 2024, alle 9:45 a.m. PT. Un webcast audio in diretta della presentazione sarà disponibile tramite la pagina delle Relazioni con gli Investitori sul sito web dell'azienda. Una registrazione archiviata sarà anche accessibile in un secondo momento sulla stessa pagina.
Standard BioTools (NASDAQ: LAB) anunció que su Presidente y CEO, Michael Egholm, PhD, presentará en la 43ª Conferencia Anual de J.P. Morgan Healthcare. El evento se llevará a cabo del 13 al 16 de enero en el Hotel Westin St. Francis en San Francisco, CA. La presentación del Dr. Egholm está programada para el 16 de enero de 2024, a las 9:45 a.m. PT. Un webcast de audio en vivo de la presentación estará disponible a través de la página de Relaciones con Inversores en el sitio web de la compañía. Una grabación archivada también estará disponible para acceder más tarde en la misma página.
Standard BioTools (NASDAQ: LAB)는 회사의 회장 겸 CEO인 Michael Egholm, PhD가 제43회 J.P. 모건 헬스케어 컨퍼런스에서 발표할 것이라고 발표했습니다. 이 행사는 1월 13일부터 16일까지 샌프란시스코 CA에 있는 웨스틴 세인트 프랜시스 호텔에서 열릴 예정입니다. Egholm 박사의 발표는 2024년 1월 16일 오전 9시 45분 PT로 예정되어 있습니다. 발표의 라이브 오디오 웹캐스트는 회사 웹사이트의 투자자 관계 페이지에서 접근할 수 있습니다. 같은 페이지에서 나중에 보관된 녹음도 이용할 수 있습니다.
Standard BioTools (NASDAQ: LAB) a annoncé que son président-directeur général, Michael Egholm, PhD, fera une présentation lors de la 43ème Conférence Annuelle J.P. Morgan Healthcare. L'événement se tiendra du 13 au 16 janvier à l'hôtel Westin St. Francis à San Francisco, CA. La présentation du Dr Egholm est prévue pour le 16 janvier 2024 à 9h45 PT. Un webinaire audio en direct de la présentation sera accessible via la page des Relations Investisseurs sur le site web de l'entreprise. Un enregistrement archivé sera également disponible pour une consultation ultérieure sur la même page.
Standard BioTools (NASDAQ: LAB) gab bekannt, dass sein Präsident und CEO, Michael Egholm, PhD, auf der 43. jährlichen J.P. Morgan Healthcare-Konferenz präsentieren wird. Die Veranstaltung findet vom 13. bis 16. Januar im Westin St. Francis Hotel in San Francisco, CA, statt. Dr. Egholms Präsentation ist für den 16. Januar 2024 um 9:45 Uhr PT geplant. Ein Live-Audio-Webcast der Präsentation wird über die Investor Relations-Seite der Unternehmenswebsite zugänglich sein. Eine archivierte Aufnahme wird ebenfalls zu einem späteren Zeitpunkt auf derselben Seite verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference taking place on January 13th - 16th at the Westin St. Francis Hotel in San Francisco, CA.
Dr. Egholm’s corporate presentation will be held on January 16th, 2024, at 9:45 a.m. PT.
A live audio webcast will be available to investors and other interested parties by accessing the Investor Relations page of the Company’s website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact
David Holmes
Gilmartin Group LLC
ir@standardbio.com
FAQ
When will Standard BioTools present at the J.P. Morgan Healthcare Conference?
Who is presenting for Standard BioTools at the J.P. Morgan Healthcare Conference?
Where is the 43rd Annual J.P. Morgan Healthcare Conference being held?
How can I access the live webcast of Standard BioTools' presentation?
Will there be an archived recording of the Standard BioTools presentation?
